Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
1 other identifier
observational
80
0 countries
N/A
Brief Summary
Morning urine samples of patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from November 2020 to January 2022 were collected. By scanning the morning urine samples of corresponding patients with microhyperspectral imager, machine learning and deep learning were used to classify microhyperspectral images, and the classification accuracy was greater than 85%. Thus, hyperspectral imaging technology could be used as a non-invasive diagnostic means to assist the diagnosis of glomerular diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2023
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 18, 2023
CompletedFirst Posted
Study publicly available on registry
April 4, 2023
CompletedStudy Start
First participant enrolled
May 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 20, 2023
CompletedMay 3, 2023
April 1, 2023
3 months
March 18, 2023
April 29, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Microhyperspectral image of urine specimen
Microhyperspectral images of urine samples from patients with four different glomerular diseases before treatment
2023.4-2023.10
Study Arms (4)
diabetic nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
minimal change nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
IgA nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
idiopathic membranous nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
Interventions
Microscopic hyperspectral imaging system
Eligibility Criteria
Patients with massive proteinuria were diagnosed as IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy by renal biopsy.
You may qualify if:
- Over 18 years old;
- Patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, minimal change nephropathy confirmed by renal biopsy;
- Had not received hormone and/or immunosuppressive therapy before renal biopsy;
- Complete clinical data, all signed the "Admission Certificate of Qianfoshan Hospital of Shandong Province", and agreed to use relevant medical information, biological specimen examination and examination results for scientific research.
You may not qualify if:
- There are factors causing secondary membranous nephropathy, such as immune diseases (systemic lupus erythematosus), tumors/infections (viral hepatitis), drugs or poisons, etc.;
- Severe infection: fever, cough and expectoration, sore throat, abdominal pain, diarrhea, carbuncle and furuncle and other clinical manifestations of skin and soft tissue infection, blood routine white blood cell count beyond the normal range (10Ă—109/L);
- Severe cardiovascular disease: including chronic heart failure grade 3 or above and various arrhythmias;
- Infectious diseases: active hepatitis, AIDS, syphilis, etc. ;
- Tumor evidence: it has been found that there is a certain tumor or clinical manifestations, tumor markers, etc., suggesting the possibility of tumor.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Qianfo Mountain Hospital of Shandong Province
Study Record Dates
First Submitted
March 18, 2023
First Posted
April 4, 2023
Study Start
May 30, 2023
Primary Completion
August 20, 2023
Study Completion
September 20, 2023
Last Updated
May 3, 2023
Record last verified: 2023-04